Lyell Immunopharma, Inc. Financials
This page shows Lyell Immunopharma, Inc. (LYEL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Lyell Immunopharma, Inc. has an operating margin of -748344.4%, meaning the company retains $-748344 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -588123.0% the prior year.
Lyell Immunopharma, Inc.'s revenue declined 41% year-over-year, from $61K to $36K. This contraction results in a growth score of 0/100.
Lyell Immunopharma, Inc. carries a low D/E ratio of 0.37, meaning only $0.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.28, Lyell Immunopharma, Inc. holds $5.28 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Lyell Immunopharma, Inc. generated -$150.0M in operating cash flow, capex of $780K consumed most of it, leaving -$150.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Lyell Immunopharma, Inc. generates a -110.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -89.6% the prior year.
Lyell Immunopharma, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Lyell Immunopharma, Inc. generates $0.55 in operating cash flow (-$150.0M OCF vs -$274.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Lyell Immunopharma, Inc. generated $36K in revenue in fiscal year 2025. This represents a decrease of 41.0% from the prior year.
Lyell Immunopharma, Inc.'s EBITDA was -$257.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.0% from the prior year.
Lyell Immunopharma, Inc. reported -$274.4M in net income in fiscal year 2025. This represents an increase of 20.0% from the prior year.
Lyell Immunopharma, Inc. earned $-16.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 38.8% from the prior year.
Cash & Balance Sheet
Lyell Immunopharma, Inc. generated -$150.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 7.4% from the prior year.
Lyell Immunopharma, Inc. held $60.2M in cash against $0 in long-term debt as of fiscal year 2025.
Lyell Immunopharma, Inc. had 21M shares outstanding in fiscal year 2025. This represents an increase of 44.1% from the prior year.
Margins & Returns
Lyell Immunopharma, Inc.'s operating margin was -748344.4% in fiscal year 2025, reflecting core business profitability. This is down 160221.5 percentage points from the prior year.
Lyell Immunopharma, Inc.'s net profit margin was -762355.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 200070.3 percentage points from the prior year.
Lyell Immunopharma, Inc.'s ROE was -110.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 21.0 percentage points from the prior year.
Capital Allocation
Lyell Immunopharma, Inc. invested $158.7M in research and development in fiscal year 2025. This represents a decrease of 7.5% from the prior year.
Lyell Immunopharma, Inc. invested $780K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 68.1% from the prior year.
LYEL Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6K-60.0% | $15K+87.5% | $8K+14.3% | $7K-36.4% | $11K-67.6% | $34K+161.5% | $13K+333.3% | $3K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $52.2M+85.3% | $28.2M-19.2% | $34.9M-19.8% | $43.4M-10.7% | $48.7M+23.2% | $39.5M-1.9% | $40.3M-6.7% | $43.2M |
| SG&A Expenses | $10.6M-0.7% | $10.7M+9.2% | $9.8M-30.3% | $14.0M-3.3% | $14.5M+23.4% | $11.8M-4.0% | $12.3M-9.2% | $13.5M |
| Operating Income | -$127.6M-242.6% | -$37.3M+21.0% | -$47.1M+17.8% | -$57.4M+71.5% | -$201.1M-298.3% | -$50.5M+2.0% | -$51.5M+7.3% | -$55.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$140.7M-262.3% | -$38.8M+9.0% | -$42.7M+18.2% | -$52.2M+72.8% | -$191.9M-330.5% | -$44.6M+2.7% | -$45.8M+24.5% | -$60.7M |
| EPS (Diluted) | N/A | $-2.13+26.3% | $-2.89 | $-0.18 | N/A | $-3.48+3.1% | $-3.59-1395.8% | $-0.24 |
LYEL Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $340.1M-16.6% | $408.0M+5.8% | $385.5M-10.3% | $429.8M-12.4% | $490.9M-20.7% | $619.2M-5.3% | $654.1M-5.8% | $694.2M |
| Current Assets | $260.9M-20.5% | $328.2M+16.3% | $282.2M-8.7% | $309.2M-18.6% | $379.6M-15.7% | $450.0M-10.0% | $499.8M-6.4% | $534.2M |
| Cash & Equivalents | $60.2M-51.3% | $123.6M+25.1% | $98.8M-17.9% | $120.3M+14.0% | $105.6M+5.3% | $100.3M-24.8% | $133.4M+6.2% | $125.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $91.8M+16.5% | $78.8M-8.9% | $86.5M-7.2% | $93.3M-13.7% | $108.0M+22.0% | $88.5M+1.0% | $87.6M-3.8% | $91.1M |
| Current Liabilities | $49.4M+55.0% | $31.9M-13.6% | $36.9M-10.6% | $41.3M-23.2% | $53.8M+60.5% | $33.5M+8.5% | $30.9M-4.6% | $32.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $248.2M-24.6% | $329.1M+10.1% | $298.9M-11.2% | $336.5M-12.1% | $382.8M-27.9% | $530.7M-6.3% | $566.5M-6.1% | $603.2M |
| Retained Earnings | -$1.6B-9.5% | -$1.5B-2.7% | -$1.4B-3.1% | -$1.4B-3.9% | -$1.3B-16.6% | -$1.2B-4.0% | -$1.1B-4.3% | -$1.1B |
LYEL Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.3M-12.9% | -$28.6M+17.1% | -$34.5M+37.0% | -$54.7M-15.9% | -$47.2M-34.8% | -$35.0M+8.0% | -$38.1M+9.3% | -$42.0M |
| Capital Expenditures | $304K+390.3% | $62K-63.1% | $168K-31.7% | $246K+459.1% | $44K-25.4% | $59K-82.2% | $331K+1003.3% | $30K |
| Free Cash Flow | -$32.6M-13.7% | -$28.6M+17.3% | -$34.6M+37.0% | -$55.0M-16.3% | -$47.3M-34.7% | -$35.1M+8.7% | -$38.4M+8.6% | -$42.0M |
| Investing Cash Flow | -$31.4M-1036.5% | $3.3M-73.5% | $12.6M-81.8% | $69.5M+29.8% | $53.5M+2689.6% | $1.9M-95.7% | $45.0M+104.6% | $22.0M |
| Financing Cash Flow | $222K-99.6% | $50.0M+27222.4% | $183K+18200.0% | $1K-99.8% | $437K | $0-100.0% | $862K+3092.6% | $27K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LYEL Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -2127400.0%-1879046.7pp | -248353.3%+340896.7pp | -589250.0%+230278.6pp | -819528.6%+1009080.5pp | -1828609.1%-1680065.0pp | -148544.1%+247825.1pp | -396369.2%+1456130.8pp | -1852500.0% |
| Net Margin | -2345383.3%-2086410.0pp | -258973.3%+274576.7pp | -533550.0%+212092.9pp | -745642.9%+999220.8pp | -1744863.6%-1613737.2pp | -131126.5%+221250.5pp | -352376.9%+1669856.4pp | -2022233.3% |
| Return on Equity | -56.7%-44.9pp | -11.8%+2.5pp | -14.3%+1.2pp | -15.5%+34.6pp | -50.1%-41.7pp | -8.4%-0.3pp | -8.1%+2.0pp | -10.1% |
| Return on Assets | -41.4%-31.9pp | -9.5%+1.6pp | -11.1%+1.1pp | -12.1%+27.0pp | -39.1%-31.9pp | -7.2%-0.2pp | -7.0%+1.7pp | -8.7% |
| Current Ratio | 5.28-5.0 | 10.30+2.6 | 7.65+0.2 | 7.49+0.4 | 7.06-6.4 | 13.43-2.8 | 16.19-0.3 | 16.51 |
| Debt-to-Equity | 0.37+0.1 | 0.24-0.0 | 0.29+0.0 | 0.280.0 | 0.28+0.1 | 0.17+0.0 | 0.150.0 | 0.15 |
| FCF Margin | -542583.3%-351656.7pp | -190926.7%+241898.3pp | -432825.0%+352660.7pp | -785485.7%-355613.0pp | -429872.7%-326634.5pp | -103238.2%+192338.7pp | -295576.9%+1105956.4pp | -1401533.3% |
Similar Companies
Frequently Asked Questions
What is Lyell Immunopharma, Inc.'s annual revenue?
Lyell Immunopharma, Inc. (LYEL) reported $36K in total revenue for fiscal year 2025. This represents a -41.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lyell Immunopharma, Inc.'s revenue growing?
Lyell Immunopharma, Inc. (LYEL) revenue declined by 41% year-over-year, from $61K to $36K in fiscal year 2025.
Is Lyell Immunopharma, Inc. profitable?
No, Lyell Immunopharma, Inc. (LYEL) reported a net income of -$274.4M in fiscal year 2025, with a net profit margin of -762355.6%.
What is Lyell Immunopharma, Inc.'s EBITDA?
Lyell Immunopharma, Inc. (LYEL) had EBITDA of -$257.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lyell Immunopharma, Inc.'s operating margin?
Lyell Immunopharma, Inc. (LYEL) had an operating margin of -748344.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Lyell Immunopharma, Inc.'s net profit margin?
Lyell Immunopharma, Inc. (LYEL) had a net profit margin of -762355.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Lyell Immunopharma, Inc.'s return on equity (ROE)?
Lyell Immunopharma, Inc. (LYEL) has a return on equity of -110.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Lyell Immunopharma, Inc.'s free cash flow?
Lyell Immunopharma, Inc. (LYEL) generated -$150.8M in free cash flow during fiscal year 2025. This represents a 7.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lyell Immunopharma, Inc.'s operating cash flow?
Lyell Immunopharma, Inc. (LYEL) generated -$150.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Lyell Immunopharma, Inc.'s total assets?
Lyell Immunopharma, Inc. (LYEL) had $340.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Lyell Immunopharma, Inc.'s capital expenditures?
Lyell Immunopharma, Inc. (LYEL) invested $780K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Lyell Immunopharma, Inc. spend on research and development?
Lyell Immunopharma, Inc. (LYEL) invested $158.7M in research and development during fiscal year 2025.
What is Lyell Immunopharma, Inc.'s current ratio?
Lyell Immunopharma, Inc. (LYEL) had a current ratio of 5.28 as of fiscal year 2025, which is generally considered healthy.
What is Lyell Immunopharma, Inc.'s debt-to-equity ratio?
Lyell Immunopharma, Inc. (LYEL) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lyell Immunopharma, Inc.'s return on assets (ROA)?
Lyell Immunopharma, Inc. (LYEL) had a return on assets of -80.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lyell Immunopharma, Inc.'s cash runway?
Based on fiscal year 2025 data, Lyell Immunopharma, Inc. (LYEL) had $60.2M in cash against an annual operating cash burn of $150.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lyell Immunopharma, Inc.'s Piotroski F-Score?
Lyell Immunopharma, Inc. (LYEL) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lyell Immunopharma, Inc.'s earnings high quality?
Lyell Immunopharma, Inc. (LYEL) has an earnings quality ratio of 0.55x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Lyell Immunopharma, Inc.?
Lyell Immunopharma, Inc. (LYEL) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.